Drug Trial Radar · NCT05265052
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
177
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- 3D MedicinesIndustry
- Sponsor type
- Industry
- First posted
- Mar 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.
Conditions
- Cancer Pain
Interventions
3D1002 (50 mg)(Phase IIa)Drug
1 tablet of 3D1002 per oral dose
3D1002 (100 mg)(Phase IIa)Drug
2 tablets of 3D1002 per oral dose
3D1002 (150 mg)(Phase IIa)Drug
3 tablets of 3D1002 per oral dose
3D1002 monotherapy (Phase IIb)Drug
3D1002 is administered at recommended dose with mimic OxyContin tablets.
OxyContin monotherapy (Phase IIb)Drug
OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.
3D1002 + OxyContin (Phase IIb)Drug
3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sum of pain intensity difference in the Numeric Rating Scale (NRS) within 14 days after the first study drug treatment (SPID14)Time frame: 1 to 14 days after receiving study treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.